Astellas Pharma (BMV:4503 N) - Aandelenkoers, Nieuws & Analyse

4503 N Overzicht aandelen

Manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. Meer informatie

4503 N fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	3/6

Beloningen

Verhandeld tegen 52.9% onder onze schatting van de reële waarde

De winst zal naar verwachting met 29.96% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Het dividend van 4.45% wordt niet goed gedekt door de winst of de vrije kasstromen

Grote eenmalige posten die de financiële resultaten beïnvloeden

Winstmarges (0.3%) zijn lager dan vorig jaar (9.3%)

Astellas Pharma Inc. Concurrenten

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.9b

Zhangzhou Pientzehuang Pharmaceutical

SHSE:600436

CN¥142.4b

Teva Pharmaceutical Industries

NYSE:TEVA

US$19.4b

Bayer

XTRA:BAYN

€19.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Astellas Pharma
Historische aandelenkoersen
Huidige aandelenkoers	JP¥204.11
52 Week Hoogtepunt	JP¥204.11
52 Week Laag	JP¥204.11
Bèta	0.28
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-41.73%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	4503 N	MX Pharmaceuticals	MX Markt
7D	0%	-2.5%	-1.0%
1Y	n/a	-17.5%	-3.3%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe 4503 N presteerde ten opzichte van de MX Pharmaceuticals.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe 4503 N presteerde ten opzichte van de MX markt.

Prijsvolatiliteit

Is 4503 N's price volatile compared to industry and market?
4503 N volatility
4503 N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.1%
10% least volatile stocks in MX Market	2.6%

Stabiele aandelenkoers: 4503 N heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 4503 N in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1923	14,484	Naoki Okamura	www.astellas.com

Astellas Pharma Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Astellas Pharma zich tot de beurswaarde?
4503 N fundamentele statistieken
Marktkapitalisatie	Mex$303.45b
Inkomsten(TTM)	Mex$451.39m
Inkomsten(TTM)	Mex$165.94b

672.3x

Koers/Winstverhouding

1.8x

P/S-verhouding

Is 4503 N overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
4503 N resultatenrekening (TTM)
Inkomsten	JP¥1.54t
Kosten van inkomsten	JP¥281.54b
Brutowinst	JP¥1.26t
Overige uitgaven	JP¥1.26t
Inkomsten	JP¥4.20b

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

Apr 25, 2024

Winst per aandeel (EPS)	2.34
Brutomarge	81.76%
Nettowinstmarge	0.27%
Schuld/Eigen Vermogen Verhouding	58.1%

Hoe presteerde 4503 N op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

4.4%

Huidig dividendrendement

2,783%

Uitbetalingsratio

4503 N Overzicht aandelen

Beloningen

Risicoanalyse

Astellas Pharma Inc. Concurrenten

BMV:LAB B

Mex$24.9b

SHSE:600436

CN¥142.4b

NYSE:TEVA

US$19.4b

XTRA:BAYN

€19.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society

European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer

Recent updates

Astellas Pharma Inc. Vyloy™ (Zolbetuximab-Clzb) Approved by U.S. Fda for Treatment of Advanced Gastric and Gej Cancer

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma Inc. to Report Q2, 2025 Results on Oct 30, 2024

Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society

European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer

Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy

Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer

Astellas Pharma Inc. Receives Positive Chmp Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma Inc. to Report Q1, 2025 Results on Aug 01, 2024

U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date

Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024

Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024

U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer

Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan

Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDA

Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

High number of new directors

Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.S

Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024

Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause

Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting

Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus Chemotherapy

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Astellas Receives Positive Chmp Opinion for Veoza (Fezolinetant)

Astellas Pharma Inc. to Report Q2, 2024 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Astellas Pharma Inc. Announces China's National Medical Products Administration Accepts New Drug Application for Xtandi®? (Enzalutamide) in Metastatic Hormone-S Sensitive Prostate Cancer

Astellas Pharma Inc. Announces Positive 24-Month Topline Results from the Phase 3 GATHER2 Clinical Trial Evaluating the Efficacy and Safety of IZERVAY

European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Astellas Pharma Inc. Announces European Medicines Agency Accepts for Regulatory Review the Marketing Authorization Application for Avacincaptad Pegol

U.S. FDA Accepts Astellas Pharma US, Inc.'s sNDA for CRESEMBA® (isavuconazonium sulfate) in Children

Astellas Pharma Inc. Announces the U.S. Food and Drug Administration Approves Izervay (Avacincaptad Pegol Intravitreal Solution) for the Treatment of Geographic At the 12-Month Primary Endpoint Across Two Phase 3 Clinical Trials

Astellas Pharma Inc. Revises Consolidated Earnings Guidance on Full Basis for the Full-Year 2023

China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab

European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab

Astellas Pharma Inc. to Report Q1, 2024 Results on Aug 01, 2023

Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application

Astellas Pharma Inc. Announces Positive Topline Results from the Phase 3b DayLIGHT Clinical Trial for Fezolinetant

Astellas Pharma Inc. Confirms Unfavorable District Court Decision in Myrbetriq U.S. Patent Trial

Astellas Pharma Inc. Announces Submission of New Drug Application to Japan's Ministry of Health, Labour and Welfare for Zolbetuximab

Astellas' Veozah Tm (Fezolinetant) Approved by U.S. Fda for Treatment of Vasomotor Symptoms Due to Menopause

Astellas Pharma Inc. Provides Update on Fezolinetant New Drug Application in U.S

Third quarter 2023 earnings released: EPS: JP¥26.56 (vs JP¥32.86 in 3Q 2022)

Astellas Pharma Inc. Reaffirms Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Astellas Pharma Inc. Announces CEO Changes, Effective April 1, 2023